

WHO region	Demography 2003				% of the population carrying			Affected conceptions (per 1000)			Affected births (% of under-5 mortality)
	Population (millions)	Crude birth rate	Annual births (1000s)	Under-5 mortality rate	Sig-nificant variant ^a	α^+ thalas-saemia ^b	Any variant ^c	Sickle-cell disorders ^d	Thalas-saemias ^e	Total	
African	586	39.0	22 895	168	18.2	41.2	44.4	10.68	0.07	10.74	6.4
American	853	19.5	16 609	27	3.0	4.8	7.5	0.49	0.06	0.54	2.0
Eastern Mediterranean	573	29.3	16 798	108	4.4	19.0	21.7	0.84	0.70	1.54	1.4
European	879	11.9	10 459	25	1.1	2.3	3.3	0.07	0.13	0.20	0.8
South-east Asian	1 564	24.4	38 139	83	6.6	44.6	45.5	0.68	0.66	1.34	1.6
Western Pacific	1 761	13.6	23 914	38	3.2	10.3	13.2	0.00	0.76	0.76	2.0
World	6 217	20.7	128 814	81	5.2	20.7	24.0	2.28	0.46	2.73	3.4

^a Significant variants include Hb S, Hb C, Hb E, Hb D etc. β thalassaemia, α^0 thalassaemia.

^b α^+ thalassaemia includes heterozygous and homozygous α^+ thalassaemia.

^c Allows for (1) coincidence of α and β variants, and (2) harmless combinations of β variants.

^d Sickle-cell disorders include SS, SC, S/ β thalassaemia.

^e Thalassaemias include homozygous β thalassaemia, haemoglobin E/ β thalassaemia, homozygous α^0 thalassaemia, α^0/α^+ thalassaemia (haemoglobin H disease).